Cefazolin, Bacitracin, Cefalexin — Competitive Intelligence Brief

Cefazolin, Bacitracin, Cefalexin (Cefazolin, Bacitracin, Cefalexin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic combination. Area: Infectious Disease.

phase 3 Beta-lactam antibiotic combination Penicillin-binding proteins (PBPs); bacterial cell wall Infectious Disease Small molecule

Target snapshot

Cefazolin, Bacitracin, Cefalexin (Cefazolin, Bacitracin, Cefalexin) — Population Health Research Institute. This is a combination of three beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cefazolin, Bacitracin, Cefalexin TARGET	Cefazolin, Bacitracin, Cefalexin	Population Health Research Institute	phase 3	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs); bacterial cell wall
Fosfomycin and imipenem	Fosfomycin and imipenem	Juan A. Arnaiz	marketed	Beta-lactam antibiotic combination	Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins)
Azithromycin and amoxicillin	Azithromycin and amoxicillin	University of Alabama at Birmingham	marketed	Macrolide and beta-lactam antibiotic combination	Bacterial 50S ribosomal subunit (azithromycin); bacterial cell wall peptidoglycan (amoxicillin)
Pivmecillinam/augmentin	Pivmecillinam/augmentin	Radboud University Medical Center	marketed	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Gentamicin + narrow spectrum betalactam	Gentamicin + narrow spectrum betalactam	University Hospital, Akershus	marketed	Aminoglycoside + Beta-lactam antibiotic combination	Bacterial 30S ribosome (gentamicin); Penicillin-binding proteins (beta-lactam)
Ceftolozane-tazobactam + Meropenem	Ceftolozane-tazobactam + Meropenem	National University of Singapore	marketed	Beta-lactam antibiotic combination	Bacterial penicillin-binding proteins (PBPs); beta-lactamase inhibition
Rabeprazole, Amoxicillin	Rabeprazole, Amoxicillin	Mackay Memorial Hospital	marketed	Proton pump inhibitor + Beta-lactam antibiotic combination	H+/K+-ATPase (rabeprazole); Bacterial penicillin-binding proteins (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic combination class)

1. Juan A. Arnaiz · 1 drug in this class
2. National University of Singapore · 1 drug in this class
3. Population Health Research Institute · 1 drug in this class
4. Radboud University Medical Center · 1 drug in this class
5. UPECLIN HC FM Botucatu Unesp · 1 drug in this class